keyword
MENU ▼
Read by QxMD icon Read
search

Vlp

keyword
https://www.readbyqxmd.com/read/29338048/ebola-virus-requires-a-host-scramblase-for-externalization-of-phosphatidylserine-on-the-surface-of-viral-particles
#1
Asuka Nanbo, Junki Maruyama, Masaki Imai, Michiko Ujie, Yoichiro Fujioka, Shinya Nishide, Ayato Takada, Yusuke Ohba, Yoshihiro Kawaoka
Cell surface receptors for phosphatidylserine contribute to the entry of Ebola virus (EBOV) particles, indicating that the presence of phosphatidylserine in the envelope of EBOV is important for the internalization of EBOV particles. Phosphatidylserine is typically distributed in the inner layer of the plasma membrane in normal cells. Progeny virions bud from the plasma membrane of infected cells, suggesting that phosphatidylserine is likely flipped to the outer leaflet of the plasma membrane in infected cells for EBOV virions to acquire it...
January 16, 2018: PLoS Pathogens
https://www.readbyqxmd.com/read/29338045/protection-induced-by-virus-like-particle-vaccine-containing-tandem-repeat-gene-of-respiratory-syncytial-virus-g-protein
#2
Ah-Ra Kim, Dong-Hun Lee, Su-Hwa Lee, Ilaria Rubino, Hyo-Jick Choi, Fu-Shi Quan
Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract illness in infants, young children and the elderly. However, there is no licensed vaccine available against RSV infection. In this study, we generated virus-like particle (VLP) vaccine and investigated the vaccine efficacy in a mouse model. For VLP vaccines, tandem gene (1-780 bp) for V1 VLPs and tandem repeat gene (repeated 450-780 bp) for V5 VLPs were constructed in pFastBacTM vectors, respectively. Influenza matrix protein 1 (M1) was used as a core protein in the VLPs...
2018: PloS One
https://www.readbyqxmd.com/read/29325819/explanations-for-the-high-potency-of-hpv-prophylactic-vaccines
#3
John Schiller, Doug Lowy
HPV L1 virus-like particle (VLP) vaccines administered in a prime/boost series of three injections over six months have demonstrated remarkable prophylactic efficacy in clinical trials and effectiveness in national immunization programs with high rates of coverage. There is mounting evidence that the vaccines have similar efficacy and effectiveness even when administered in a single dose. The unexpected potency of one dose of these VLP vaccines may largely be attributed to structural features of the particles, which lead to the efficient generation of long-lived antigen-specific antibody-producing cells and unique features of the virus life cycle that make the HPV virions highly susceptible to antibody-mediated inhibition of infection...
January 8, 2018: Vaccine
https://www.readbyqxmd.com/read/29324805/intranasal-vaccination-with-m2e5x-virus-like-particles-induces-humoral-and-cellular-immune-responses-conferring-cross-protection-against-heterosubtypic-influenza-viruses
#4
Young-Tae Lee, Eun-Ju Ko, Youri Lee, Ki-Hye Kim, Min-Chul Kim, Yu-Na Lee, Sang-Moo Kang
Current influenza vaccines do not provide broad cross-protection. Here, we report that intranasal vaccination with virus-like particles containing the highly conserved multiple ectodomains of matrix protein 2 (M2e5x VLP) of influenza virus induces broad cross-protection by M2-specific humoral and cellular immune responses. M2e5x VLP intranasal vaccination prevented severe weight loss, attenuated inflammatory cytokines and cellular infiltrates, and lowered viral loads, and induced germinal center phenotypic B and plasma cells...
2018: PloS One
https://www.readbyqxmd.com/read/29323105/enterovirus-d68-virus-like-particles-expressed-in-pichia-pastoris-potently-induce-neutralizing-antibody-responses-and-confer-protection-against-lethal-viral-infection-in-mice
#5
Chao Zhang, Xueyang Zhang, Wei Zhang, Wenlong Dai, Jing Xie, Liping Ye, Hongli Wang, Huan Chen, Qingwei Liu, Sitang Gong, Lanlan Geng, Zhong Huang
Enterovirus D68 (EV-D68) has been increasingly associated with severe respiratory illness and neurological complications in children worldwide. However, no vaccine is currently available to prevent EV-D68 infection. In the present study, we investigated the possibility of developing a virus-like particle (VLP)-based EV-D68 vaccine. We found that co-expression of the P1 precursor and 3CD protease of EV-D68 in Pichia pastoris yeast resulted in the generation of EV-D68 VLPs, which were composed of processed VP0, VP1, and VP3 capsid proteins and were visualized as ~30 nm spherical particles...
January 10, 2018: Emerging Microbes & Infections
https://www.readbyqxmd.com/read/29309412/a-tetravalent-virus-like-particle-vaccine-designed-to-display-domain-iii-of-dengue-envelope-proteins-induces-multi-serotype-neutralizing-antibodies-in-mice-and-macaques-which-confer-protection-against-antibody-dependent-enhancement-in-ag129-mice
#6
Viswanathan Ramasamy, Upasana Arora, Rahul Shukla, Ankur Poddar, Rajgokul K Shanmugam, Laura J White, Melissa M Mattocks, Rajendra Raut, Ashiya Perween, Poornima Tyagi, Aravinda M de Silva, Siddhartha K Bhaumik, Murali Krishna Kaja, François Villinger, Rafi Ahmed, Robert E Johnston, Sathyamangalam Swaminathan, Navin Khanna
BACKGROUND: Dengue is one of the fastest spreading vector-borne diseases, caused by four antigenically distinct dengue viruses (DENVs). Antibodies against DENVs are responsible for both protection as well as pathogenesis. A vaccine that is safe for and efficacious in all people irrespective of their age and domicile is still an unmet need. It is becoming increasingly apparent that vaccine design must eliminate epitopes implicated in the induction of infection-enhancing antibodies. METHODOLOGY/PRINCIPAL FINDINGS: We report a Pichia pastoris-expressed dengue immunogen, DSV4, based on DENV envelope protein domain III (EDIII), which contains well-characterized serotype-specific and cross-reactive epitopes...
January 8, 2018: PLoS Neglected Tropical Diseases
https://www.readbyqxmd.com/read/29306508/a-virus-like-particle-vaccine-candidate-for-influenza-a-virus-based-on-multiple-conserved-antigens-presented-on-hepatitis-b-tandem-core-particles
#7
Alejandro Ramirez, Stephen Morris, Sophie Maucourant, Isabella D'Ascanio, Vincenzo Crescente, I-Na Lu, Sophie Farinelle, Claude P Muller, Michael Whelan, William Rosenberg
Existing Influenza A virus (IAV) vaccines target variable parts of the virus that may change between seasons. Vaccine design relies on predicting the predominant circulating influenza strains but when there is a mismatch between vaccine and circulating strains, efficacy is sub-optimal. Furthermore, current approaches provide limited protection against emerging influenza strains that may cause pandemics. One solution is to design vaccines that target conserved protein domains of influenza, which remain largely unchanged over time and are likely to be found in emergent variants...
January 3, 2018: Vaccine
https://www.readbyqxmd.com/read/29305551/development-and-evaluation-of-a-broad-bead-based-multiplex-immunoassay-to-measure-igg-seroreactivity-against-human-polyomaviruses
#8
Sergio Kamminga, Els van der Meijden, Herman F Wunderink, Antoine Touzé, Hans L Zaaijer, Mariet C W Feltkamp
Introduction The family of polyomaviruses, which cause severe disease in immunocompromised hosts, has expanded substantially in recent years. To accommodate measurement of IgG seroresponses against all currently known human polyomavirus (HPyV), including the Lyon IARC polyomavirus (LIPyV), we extended our custom multiplex bead-based HPyV immunoassay and evaluated the performance of this pan-HPyV immunoassay.Methods VP1 protein of fifteen HPyVs belonging to 13 polyomavirus species were expressed as recombinant glutathione S-transferase (GST) fusion proteins and coupled to fluorescent Luminex beads...
January 5, 2018: Journal of Clinical Microbiology
https://www.readbyqxmd.com/read/29300162/production-of-gp64-free-virus-like-particles-from-baculovirus-infected-insect-cells
#9
Lorena C S Chaves, Bergmann M Ribeiro, Gary W Blissard
The retroviral Gag protein is frequently used to generate 'virus-like particles' (VLPs) for a variety of applications. Retroviral Gag proteins self-assemble and bud at the plasma membrane to form enveloped VLPs that resemble natural retrovirus virions, but contain no viral genome. The baculovirus expression vector system has been used to express high levels of the retroviral Gag protein to produce VLPs. However, VLP preparations produced from baculovirus-infected insect cells typically contain relatively large concentrations of baculovirus budded virus (BV) particles, which are similar in size and density to VLPs, and thus may be difficult to separate when purifying VLPs...
January 4, 2018: Journal of General Virology
https://www.readbyqxmd.com/read/29295756/a-virus-like-particle-vaccine-confers-protection-against-enterovirus-d68-lethal-challenge-in-mice
#10
Wenlong Dai, Chao Zhang, Xueyang Zhang, Pei Xiong, Qingwei Liu, Sitang Gong, Lanlan Geng, Dongming Zhou, Zhong Huang
Enterovirus D68 (EV-D68) is increasingly associated with severe acute respiratory infection and acute flaccid myelitis (AFM) in children around the world. However, neither vaccines nor therapeutic drugs are available for EV-D68. Here we report the development of a virus-like particle (VLP) based experimental EV-D68 vaccine. We found that EV-D68 VLPs could be successfully generated in insect cells infected with a recombinant baculovirus co-expressing the P1 precursor and 3CD protease of EV-D68. Biochemical and electron microscopic analyses revealed that EV-D68 VLPs were composed of VP0, VP1, and VP3 capsid proteins derived from precursor P1 and were visualized as spherical particles of ∼30 nm in diameter...
December 30, 2017: Vaccine
https://www.readbyqxmd.com/read/29282308/b-cell-intrinsic-myd88-signaling-promotes-initial-cell-proliferation-and-differentiation-to-enhance-the-germinal-center-response-to-a-virus-like-particle
#11
Meijie Tian, Zhaolin Hua, Sheng Hong, Zhimin Zhang, Can Liu, Lin Lin, Jiaorong Chen, Wei Zhang, Xuyu Zhou, Fuping Zhang, Anthony L DeFranco, Baidong Hou
Although TLR signaling in B cells has been implicated in the germinal center (GC) responses during viral infections and autoimmune diseases, the underlying mechanism is unclear. Bacterial phage Qβ-derived virus-like particle (Qβ-VLP) contains TLR ligands, which can enhance Qβ-VLP-induced Ab response, including GC response, through TLR/MyD88 signaling in B cells. In this study, by examining Ag-specific B cell response to Qβ-VLP, we found that lack of B cell MyD88 from the beginning of the immune response led to a more severe defect in the GC scale than abolishing MyD88 at later time points of the immune response...
December 27, 2017: Journal of Immunology: Official Journal of the American Association of Immunologists
https://www.readbyqxmd.com/read/29276514/cross-protective-efficacy-of-influenza-virus-m2e-containing-virus-like-particles-is-superior-to-hemagglutinin-vaccines-and-variable-depending-on-the-genetic-backgrounds-of-mice
#12
Yu-Jin Kim, Young-Tae Lee, Min-Chul Kim, Yu-Na Lee, Ki-Hye Kim, Eun-Ju Ko, Jae-Min Song, Sang-Moo Kang
Influenza virus M2 extracellular domain (M2e) has been a target for developing cross-protective vaccines. However, the efficacy and immune correlates of M2e vaccination are poorly understood in the different host genetic backgrounds in comparison with influenza vaccines. We previously reported the cross-protective efficacy of virus-like particle (M2e5x VLP) vaccines containing heterologous tandem M2e repeats (M2e5x) derived from human, swine, and avian influenza viruses. In this study to gain better understanding of cross-protective influenza vaccines, we compared immunogenicity and efficacy of M2e5x VLP, H5 hemagglutinin VLP (HA VLP), and inactivated H3N2 virus (H3N2i) in wild-type strains of BALB/c and C57BL/6 mice, and CD4 and CD8 knockout (KO) mice...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/29259601/preclinical-development-and-production-of-virus-like-particles-as-vaccine-candidates-for-hepatitis-c
#13
REVIEW
Makutiro Ghislain Masavuli, Danushka K Wijesundara, Joseph Torresi, Eric J Gowans, Branka Grubor-Bauk
Hepatitis C Virus (HCV) infects 2% of the world's population and is the leading cause of liver disease and liver transplantation. It poses a serious and growing worldwide public health problem that will only be partially addressed with the introduction of new antiviral therapies. However, these treatments will not prevent re-infection particularly in high risk populations. The introduction of a HCV vaccine has been predicted, using simulation models in a high risk population, to have a significant effect on reducing the incidence of HCV...
2017: Frontiers in Microbiology
https://www.readbyqxmd.com/read/29246516/isolation-of-recombinant-hepatitis-b-surface-antigen-with-antibody-conjugated-superparamagnetic-fe3o4-sio2-core-shell-nanoparticles
#14
Mehdi Mostafaei, Seyed Nezamedin Hosseini, Maryam Khatami, Amin Javidanbardan, Abbas Akhavan Sepahy, Ebadullah Asadi
In the production process of recombinant Hepatitis B surface antigen (rHBsAg) various separation techniques are used to purify this virus-like particle (VLP). In this study, we developed antibody-conjugated super-paramagnetic Fe3O4/SiO2 core-shell nanoparticles as a highly selective method for isolation of expressed rHBsAg in yeast Pichia pastoris. For this purpose, first, iron oxide magnetic nanoparticles (MNPs) were prepared by co-precipitation method in alkali media and coated with silica. Then the surface was activated by amine groups and conjugated with oxidized antibodies...
December 12, 2017: Protein Expression and Purification
https://www.readbyqxmd.com/read/29246474/functionality-and-avidity-of-norovirus-specific-antibodies-and-t-cells-induced-by-gii-4-virus-like-particles-alone-or-co-administered-with-different-genotypes
#15
Maria Malm, Kirsi Tamminen, Suvi Heinimäki, Timo Vesikari, Vesna Blazevic
Norovirus (NoV) is the main cause of acute gastroenteritis worldwide across all age groups. Current NoV vaccine candidates are based on non-infectious highly immunogenic virus-like particles (VLPs) produced in cell cultures in vitro. As NoVs infecting human population are highly divergent, it is proposed that the vaccine should contain at least two different NoV genotypes, potentially affecting the immunogenicity of each other. We investigated the immunogenicity of NoV GII.4 VLPs administered by intramuscular (IM) or intradermal (ID) injections to BALB/c mice either alone or co-delivered with genogroup I (GI) and other genogroup GII VLPs...
December 12, 2017: Vaccine
https://www.readbyqxmd.com/read/29242243/an-infrared-dye-conjugated-virus-like-particle-for-the-treatment-of-primary-uveal-melanoma
#16
Rhonda C Kines, Isabella Varsavsky, Sanghamitra Choudhary, Debaditya Bhattacharya, Sean Spring, Roger J McLaughlin, Shin J Kang, Hans E Grossniklaus, Demitrios G Vavvas, Stephen Monks, John R MacDougall, Elisabet de Los Pinos, John T Schiller
The work outlined herein describes AU-011, a novel recombinant papillomavirus-like particle (VLP) drug conjugate and its initial evaluation as a potential treatment for primary uveal melanoma. The VLP is conjugated with a phthalocyanine photosensitizer, IRDye 700DX, that exerts its cytotoxic effect through photo-activation with a near-infrared laser. We assessed the anti-cancer properties of AU-011 in vitro utilizing a panel of human cancer cell lines and in vivo using murine subcutaneous and rabbit orthotopic xenograft models of uveal melanoma...
December 14, 2017: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/29230222/single-dose-of-consensus-hemagglutinin-based-virus-like-particles-vaccine-protects-chickens-against-divergent-h5-subtype-influenza-viruses
#17
Peipei Wu, Jihu Lu, Xuehua Zhang, Mei Mei, Lei Feng, Daxin Peng, Jibo Hou, Sang-Moo Kang, Xiufan Liu, Yinghua Tang
The H5 subtype highly pathogenic avian influenza (HPAI) virus is one of the greatest threats to global poultry industry. To develop broadly protective H5 subunit vaccine, a recombinant consensus HA sequence (rHA) was constructed and expressed in virus-like particles (rHA VLPs) in the baculovirus-insect cell system. The efficacy of the rHA VLPs vaccine with or without immunopotentiator (CVCVA5) was assessed in chickens. Compared to the commercial Re6 or Re6-CVCVA5 vaccines, single dose immunization of chickens with rHA VLPs or rHA-CVCVA5 vaccines induced higher levels of serum hemagglutinin inhibition titers and neutralization titers, mucosal antibodies, IFN-γ and IL-4 cytokines in sera, and cytotoxic T lymphocyte responses...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/29228524/evaluation-of-antibody-and-cytokines-responses-in-intranasally-and-intramuscularly-administrated-balb-c-mice-with-influenza-virus-like-particle
#18
Haideh Nadmdari, Mohsen Keshavarz, Talat Mokhtari-Azad, Farhad Rezaei
We previously developed an influenza virus like particle with HA, M, and NA proteins using Bac-to-Bac expression system and SF9 cell line. To evaluate the immunogenicity of our construct, we assessed the humoral, cytokine induced by H1N1-VLP in BALB/c mice immunized intranasally and intramuscularly. Enzyme-linked immunosorbent assay and Relative quantitative real-time PCR were used to evaluate the antibody (IgG and IgA) and mRNA levels of IL-6, IL-4, IL-10 and IFN-g in PBMCs. Our results showed that VLP was capable of intranasal (I...
October 2017: Acta Medica Iranica
https://www.readbyqxmd.com/read/29212932/minor-capsid-protein-l2-polytope-induces-broad-protection-against-oncogenic-and-mucosal-human-papillomaviruses
#19
Somayeh Pouyanfard, Gloria Spagnoli, Lorenzo Bulli, Kathrin Balz, Fan Yang, Caroline Odenwald, Hanna Seitz, Filipe C Mariz, Angelo Bolchi, Simone Ottonello, Martin Müller
The amino terminus of the human papillomavirus minor capsid protein L2 contains a major cross-neutralization epitope which provides the basis for the development of a broadly protecting HPV vaccine. Wide range of protection against different HPV types would eliminate one of the major drawbacks of the commercial, L1 based prophylactic vaccines. Previously, we have reported that insertion of the L2 epitope into a scaffold composed of bacterial thioredoxin protein generates a potent antigen inducing comprehensive protection against different animal and human papillomaviruses...
December 6, 2017: Journal of Virology
https://www.readbyqxmd.com/read/29203952/effect-of-intra-tumoral-magnetic-nanoparticle-hyperthermia-and-viral-nanoparticle-immunogenicity-on-primary-and-metastatic-cancer
#20
P Jack Hoopes, Courtney M Mazur, Bjorn Osterberg, Ailin Song, David J Gladstone, Nicole F Steinmetz, Frank A Veliz, Alicea A Bursey, Robert J Wagner, Steven N Fiering
Although there is long association of medical hyperthermia and immune stimulation, the relative lack of a quantifiable and reproducible effect has limited the utility and advancement of this relationship in preclinical/clinical cancer and non-cancer settings. Recent cancer-based immune findings (immune checkpoint modulators etc.) including improved mechanistic understanding and biological tools now make it possible to modify and exploit the immune system to benefit conventional cancer treatments such as radiation and hyperthermia...
January 2017: Proceedings of SPIE
keyword
keyword
7257
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"